Patient Introduction

Hello, my name is Debbie. I’m 29 years old and my daughter, Kayla, just turned 6 years old this past Tuesday. Kayla was diagnosed with AD when she was just 3 months old and since then we have tried so many approaches to help her get some relief, but nothing has really worked. On top of that, she has also been diagnosed with asthma. I am here today as Kayla is having frequent eczema flares and not getting enough sleep because of itching, so we aren’t sleeping either. I have been getting calls from school that she hasn’t been paying attention in class either. I am concerned that her eczema is not adequately managed; she is embarrassed about her skin, which makes her sad. And she scratches so much at times her skin gets infected. I have seen ads on TV about new medicines, so I joined a parent blog, and there is a lot of talk about new medicines for children with AD. I would like to discuss whether any of those new treatment options may be appropriate for Kayla. Follow the prompts on your tablet to join me for a part of the discussion.

Question #1

I can appreciate how frustrating the itch can be for Kayla as well as the family. Can you tell me how Kayla’s AD has changed since it started and what you have tried?

Answer

Question #2

I’m so sorry to hear that; I read in your chart that you also tried crisaborole; what was Kayla’s response to it?

Answer

Question #3

That is ruxolitinib, but it is approved for short-term use in children 12 years and older with mild-to-moderate AD, so it would not be indicated for Kayla. Does Kayla have any food allergies?

Answer

Question #4

That’s important to know. Certain conditions – eczema, asthma, rhinosinusitis, for example - are related through what is called type 2 inflammation. They share a common pathway and often arise together. Certain medications are indicated for more than one of these.

Answer

Question #5

Well, dupilumab is one option. It is approved in children 6 months and older for moderate to severe eczema, asthma and other conditions related to type 2 inflammation. Treatment with dupilumab could potentially help both her AD and asthma.

Answer

Question #6

Sure! 75% of children 6 to 11 years treated with dupilumab plus a topical corticosteroid showed significant improvement in eczema severity scores in a clinical trial, compared with 28% treated with steroids. This medication is injected; is that ok?

Answer

Question #7

Based on her weight, following an initial loading dose, she would need an injection once every 4 weeks. Children on dupilumab show significant improvement in symptoms, within 4 months.

Answer

Question #8

Injection-site pain is common; I’ve seen some conjunctivitis, headaches, upper respiratory tract and skin infections; however, these are mild and we usually do not have to stop the medication. Also, we can teach you to administer the medication at home.

Answer

This activity is provided by Med Learning Group.
This program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
Scroll to Top

A Special Thank You to All HCPs

Med Learning Group sends its heartful gratitude to all healthcare professionals giving their all, 24/7, during this pandemic, despite the great risks they face. We cannot thank you enough for your courage and selfless service.

Connecting you with our personalized approach to continuing Medical Education

Healthcare Business Review Award

We are thrilled to announce that we have been recognized as one of the Top 10 Health Education Services Providers by Healthcare Business Review!

This award is both an honor and a testament to our cumulative dedication to providing the best continuing medical education (CME) services to HCPs across the globe. We are proud to be part of this distinguished group and look forward to continuing to have MLG be one of the best CME providers in the country.

Thank you to Healthcare Business Review for this recognition and for shining a light on the importance of accurate and accessible healthcare education.

#TopHealthEducationProvider #MedLearningGroup #HealthcareBusinessReview #MedicalEducation
BestofAmerica

Best of America Small Business Awards
Best Website

The Best of America Small Business Website award recognizes the best website launched by a small business since 2021. Technology is a key growth enabler for small businesses. The best in tech track recognizes small businesses as experts in technology and innovation from innovators, app developers, and website creators. Visit our award-winning Ophthalmology and Optometry web portal: vision-relief.com

The Linking Approach to Education from Gap Analysis to Outcomes

Med Learning Group, a division of Ultimate Medical Academy, is a full-service accredited medical education company with commendation. Med Learning Group focuses on developing and implementing continuing education that improves healthcare practitioners’ ability to provide optimal care to their patients. Our goal is to provide high-quality education that is designed to deliver the highest level of outcomes for not only the practitioner, but also the patient. Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature.

Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature, and we focus on applying adult learning theory and principles to our programs. Even more importantly, we understand the nuances of our target audiences and design programs with a grounded understanding of how to educate both specialty audiences and general practitioners.